Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVVOSVivos Therapeutics$0.45+3.1%$0.69$0.38▼$7.95$6.03M6.14.08 million shs104,851 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVVOSVivos Therapeutics+3.13%-10.48%-32.29%-61.08%-85.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVVOSVivos Therapeutics$0.45+3.1%$0.69$0.38▼$7.95$6.03M6.14.08 million shs104,851 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVVOSVivos Therapeutics+3.13%-10.48%-32.29%-61.08%-85.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceVVOSVivos Therapeutics 2.25Hold$2.80525.56% UpsideCurrent Analyst Ratings BreakdownLatest VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $3.104/22/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.004/20/2026VVOSVivos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026VVOSVivos Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $2.50(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookVVOSVivos Therapeutics$19.57M0.32N/AN/A($0.16) per share-2.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateVVOSVivos Therapeutics-$21.17M-$2.14N/AN/AN/A-127.70%-2,325.64%-98.12%8/18/2026 (Estimated)Latest VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026VVOSVivos Therapeutics-$0.45-$0.52-$0.07-$0.52$4.35 million$5.14 million4/15/2026Q4 2025VVOSVivos Therapeutics-$0.4950-$0.58-$0.0850-$0.58$7.10 million$3.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioVVOSVivos Therapeutics3.310.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipVVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipVVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableVVOSVivos Therapeutics16013.90 million13.60 millionOptionableVVOS HeadlinesRecent News About These CompaniesVivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred EquityJune 22, 2026 | globenewswire.comVivos Therapeutics (NASDAQ:VVOS) & XORTX Therapeutics (NASDAQ:XRTX) Head-To-Head ReviewJune 16, 2026 | americanbankingnews.comVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingJune 11, 2026 | globenewswire.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to ...June 10, 2026 | markets.businessinsider.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsJune 10, 2026 | globenewswire.comVivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | quiverquant.comQVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | globenewswire.comVivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial PositionJune 5, 2026 | quiverquant.comQVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingJune 5, 2026 | globenewswire.comVivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic ShiftsMay 29, 2026 | finance.yahoo.comVivos Therapeutics Balances Rapid Growth With Cash StrainMay 22, 2026 | tipranks.comVivos Therapeutics Earnings Call: Growth Meets Cash StrainMay 21, 2026 | tipranks.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 21, 2026 | finanznachrichten.deVivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call TranscriptMay 21, 2026 | seekingalpha.comVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 20, 2026 | globenewswire.comVivos Therapeutics Delays Quarterly FilingMay 15, 2026 | tipranks.comAnalysts see 200%+ upside in these 3 high-risk stocks: here's why?May 9, 2026 | invezz.comIVivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47April 29, 2026 | msn.comVivos Therapeutics Faces Nasdaq Listing Compliance ChallengesApril 22, 2026 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call TranscriptApril 17, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVVOS Company DescriptionsVivos Therapeutics NASDAQ:VVOS$0.45 +0.01 (+3.13%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.45 0.00 (-0.13%) As of 06/26/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
